F2G’s chief executive said the antifungal developer plans to resubmit olorofim to the FDA after completing Phase 3 data collection expected this June. Olorofim, an oral antifungal targeting difficult mold infections, had its initial regulatory dossier delayed pending additional clinical evidence; the company is raising funds and preparing for the planned resubmission. Management’s public comments outline a pathway to reengage regulators with augmented efficacy and safety datasets. The update will be watched by hospitals and ID practitioners that face limited options for multi‑drug‑resistant fungal infections.